

Huri Ozdogan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9399263/publications.pdf>

Version: 2024-02-01

38
papers

2,074
citations

430874

18
h-index

302126

39
g-index

40
all docs

40
docs citations

40
times ranked

2075
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 644-651.	0.9	393
2	Country as the primary risk factor for renal amyloidosis in familial mediterranean fever. <i>Arthritis and Rheumatism</i> , 2007, 56, 1706-1712.	6.7	243
3	Colchicine Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus Statement. <i>Pediatrics</i> , 2007, 119, e474-e483.	2.1	230
4	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 799-805.	0.9	215
5	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 635-641.	0.9	145
6	Familial Mediterranean Fever. <i>Presse Medicale</i> , 2019, 48, e61-e76.	1.9	104
7	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. <i>Rheumatology</i> , 2017, 56, 2102-2108.	1.9	84
8	Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. <i>Arthritis Research and Therapy</i> , 2015, 17, 243.	3.5	83
9	Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1051-1056.	0.9	83
10	Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency. <i>Rheumatology International</i> , 2018, 38, 129-136.	3.0	63
11	FMF50: a score for assessing outcome in familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 897-901.	0.9	57
12	Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 105.	2.7	41
13	Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1362-1369.	0.9	39
14	Canakinumab for the treatment of familial Mediterranean fever. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 393-404.	3.0	37
15	Diagnostic utility of a targeted next-generation sequencing gene panel in the clinical suspicion of systemic autoinflammatory diseases: a multi-center study. <i>Rheumatology International</i> , 2019, 39, 911-919.	3.0	37
16	A familial syndrome of pericarditis, arthritis, camptodactyly, and coxa vara. <i>Arthritis and Rheumatism</i> , 1986, 29, 436-438.	6.7	32
17	A survey of phenotype II in familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 910-913.	0.9	23
18	Necrotizing vasculitis associated with familial Mediterranean fever. <i>American Journal of Medicine</i> , 2004, 117, 516-519.	1.5	19

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever. <i>Rheumatology</i> , 2020, 59, 3892-3899.	1.9	18
20	<i>LACC1</i> Gene Defects in Familial Form of Juvenile Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 726-728.	2.0	17
21	Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies. <i>Rheumatology International</i> , 2018, 38, 607-622.	3.0	12
22	The efficacy of anti- IL-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102332.	2.0	11
23	Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience. <i>Rheumatology</i> , 2021, 60, 2327-2332.	1.9	11
24	Polyarteritis nodosa: lessons from 25 years of experience. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 52-56.	0.8	9
25	Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin. <i>Internal and Emergency Medicine</i> , 2017, 12, 1059-1067.	2.0	7
26	Soluble TREM-1 Levels in Familial Mediterranean Fever Related AA-Amyloidosis. <i>Immunological Investigations</i> , 2021, 50, 273-281.	2.0	6
27	Exacerbation of Behçet's syndrome and familial Mediterranean fever with menstruation. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 108, 95-99.	0.8	6
28	Development of normative data for cylindrical grasp pressure. <i>International Journal of Industrial Ergonomics</i> , 2011, 41, 509-519.	2.6	5
29	Effects of serial casting in the treatment of flexion contractures of proximal interphalangeal joints in patients with rheumatoid arthritis and juvenile idiopathic arthritis: A retrospective study. <i>Journal of Hand Therapy</i> , 2016, 29, 41-50.	1.5	5
30	Late-onset familial mediterranean fever: single-center experience and literature review. <i>Internal and Emergency Medicine</i> , 2022, 17, 1301-1306.	2.0	4
31	Antibody responses to inactivated and mRNA SARS-CoV-2 vaccines in familial Mediterranean fever patients treated with interleukin-1 inhibitors. <i>Rheumatology</i> , 2022, 61, S1194-S1196.	1.9	4
32	Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine. <i>Journal of Medical Virology</i> , 2022, 94, 3431-3437.	5.0	4
33	The Emerging Treatments in Familial Mediterranean Fever. <i>Rare Diseases of the Immune System</i> , 2015, , 137-157.	0.1	3
34	Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates. <i>Rheumatology International</i> , 2021, , 1.	3.0	3
35	Other autoinflammatory disease genes in an FMF-prevalent population: a homozygous MVK mutation and a novel heterozygous TNFRSF1A mutation in two different Turkish families with clinical FMF. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 108, 75-81.	0.8	2
36	Familial Mediterranean fever: misdiagnosis and diagnostic delay in Turkey. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 121, 119-124.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Frequency of AA amyloidosis has decreased in Behçet's syndrome: a retrospective study with long-term follow-up and a systematic review. <i>Rheumatology</i> , 2022, 62, 9-18.	1.9	2
38	Effect of colchicine on serum lipid levels. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S136.	0.8	1